Shape

Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immune (I&I) diseases with high unmet need.

Close-up of photo of a woman’s chest, shoulder, and arm with atopic dermatis rash on arm

Our philosophy is simple.

Our goal is to discover and develop new differentiated therapies for a range of I&I indications. We aim to accomplish this goal by focusing on known biologic drivers of disease and utilizing advanced antibody engineering to develop product candidates with optimized properties that have the potential to overcome limitations of existing therapies. We believe our approach will enable us to develop a portfolio of therapies that are differentiated compared to the currently available standards of care and address unmet medical needs for I&I indications.

Improving treatment options for people with atopic dermatitis and chronic obstructive pulmonary disease

Our initial focus is atopic dermatitis (AD) and chronic obstructive pulmonary disease (COPD).

AD is a chronic inflammatory skin disorder that is estimated to affect 40 million adults and 18 million children in the United States, France, Germany, Italy, Japan, Spain and the United Kingdom. Despite recent advancements in treatment, a significant number of people living with AD continue to suffer from active disease. Today’s treatments are associated with many challenges, including a high frequency of injections that may lead to poor compliance.

COPD is a progressive respiratory disease that is estimated to affect approximately 10% of the global population 40 years of age and older. Despite recent advancements in COPD treatment, a significant number of people continue to suffer and die from the disease.

Our antibody programs are designed to overcome limitations of existing therapies by leveraging well-established mechanisms and incorporating advanced antibody engineering to optimize half-life and other properties. Based on our preclinical studies, we believe APG777 can be dosed either every two or every three months in maintenance, which, if our clinical trials are successful, would represent a significant improvement compared to currently available antibodies that are dosed every two to four weeks. We believe each of our programs has potential for broad application across multiple I&I indications.

Pipeline

STRATEGY
PROGRAM
Discovery
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
NEXT ANTICIPATED MILESTONES

Best-in-class monotherapy in AD

Higher exposures for better efficacy with less frequent dosing

IL-13

APG777

ATOPIC DERMATITIS

ATOPIC DERMATITIS

PHASE 2

  • 2H 2025: Phase 2 16-week induction PoC data

Best-in-class mAbs for combinations

Strategic optionality to combine orthogonal mechanisms across pipeline

IL-4Rα

APG808

HEALTHY VOLUNTEERS

HEALTHY VOLUNTEERS

PHASE 1

  • Q4 2024: Initial Phase 1 PK and safety in HVs

OX40L

APG990

HEALTHY VOLUNTEERS

HEALTHY VOLUNTEERS

PHASE 1

  • 2025: Initial Phase 1 PK & safety in HVs

TSLP

APG333

DISCOVERY

  • 2024: DC nomination
  • 2025: Initiate Phase 1 PK & safety in HVs

First- or best-in-class combination approaches

Rational combinations to drive broader + deeper responses

IL-13 ± OX40L

APG777 ± APG990

ATOPIC DERMATITIS

ATOPIC DERMATITIS

PRE-CLINICAL

  • 2025: Clinical trial initiation

IL-13 ± TSLP

APG777 ± APG333

ASTHMA

ASTHMA

PRE-CLINICAL

  • TBD: Clinical trial initiation1

IL-13/IL-4RΑ + OX40L/TSLP

ADDITIONAL COMBINATION(S)

COPD

COPD

DISCOVERY

  • Q4 2024: Additional combination(s) to be announced at R&D Day

Pending final data from our Phase 1 trial of APG777 in healthy volunteers, we may initiate a Phase 2 trial in asthma and expect to further evaluate opportunities to develop APG777 for other I&I indications, including alopecia areata, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and prurigo nodularis.

(1)